Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors
    Journal Article

    Liu, D.; Jee, J.; Drilon, A.; Heilmann, A. M.; Allen, J. M.; Schrock, A. B.; Keller-Evans, R. B.; Li, B. T.
    Cancer Research Communications (2025)

    Fulltext@MSK | Save
  • Top advances of the year: Neoadjuvant immunotherapy in melanoma
    Editorial

    Chen, M. F.; Postow, M. A.
    Cancer (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study
    Meeting Abstract

    Dizman, N.; Doshi, S. D.; Knezevic, A.; Feinaj, A.; Sayegh, N.; Hobeika, C.; Alaghehbandan, R.; Rives, H.; Zengin, Z. B.; Braun, D. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC)
    Meeting Abstract

    Madsen, K. N.; Labaki, C.; Saad, E.; Alchoueiry, M.; Bi, K.; Hobeika, C.; Bakouny, Z.; Priolo, C.; Khabibullin, D.; Schindler, N. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma
    Meeting Abstract

    Khandwala, Y.; Ruthen, N.; Kotecha, R. R.; Russo, P.; Coleman, J.; Reznik, E.; Hakimi, A. A.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Punekar, S. R.; Hong, D. S.; Luo, J.; Ou, S. H. I.; Johnson, M. L.; Spira, A.; Garrido-Laguna, I.; Goldman, J. W.; Herzberg, B.; Saltos, A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • PYNNACLE phase II assessing rezatapopt in patients with advanced solid tumors, including lung cancer, harboring a TP53 Y220C mutation
    Meeting Abstract

    De Miguel, M. J.; Dumbrava, E. E.; Body, A.; Eberst, L.; Frenel, J. S.; Italiano, A.; Johnson, M. L.; Kaczmar, J.; Kummar, S.; Lorusso, P. M.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save